Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2893 - Over-expression of Shh is prognostic marker in patients with extensive stage small cell lung cancer.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Seungtaek Lim

Citation

Annals of Oncology (2018) 29 (suppl_8): viii596-viii602. 10.1093/annonc/mdy298

Authors

S. Lim1, J. Kim1, S.Y. Park2

Author affiliations

  • 1 Hematooncology, Wonju Severance Christianity Hospital, 220-701 - Gangwon-do/KR
  • 2 Pathology, Konyang Unicversity Hospital, Daejeon/KR
More

Resources

Abstract 2893

Background

Recent studies have reported that the sonic hedgehog (Shh) signaling pathway plays a crucial role during tumorigenesis, angiogenesis and cellular differentiation in various malignancies including lung cancer. The aim of this study is to investigate the value of Shh pathway as prognostic markers in extensive stage small cell lung cancer (ES-SCLC) patients.

Methods

We retrospectively analyzed the data of 36 patients with ES-SCLC between 2008 and 2012 in Yonsei Cancer Center. Using formalin fixed paraffin embedded tissues of primary tumors, immunohistochemistry was done for Gli1, Patched, Shh1, and Smo. We performed survival analysis to find out the prognostic impact of these markers.

Results

All the 36 patients were treated with platinum based doublet chemotherapy. Median progression free survival and median overall survival was 6.9 months (95% CI, 6.5-7.3) and 11.7 months (95% CI, 9.1-14.3), respectively. Overall response rate was 84%. Of the 36 specimens examined, the overexpression of Gli1, Patched, Shh, and Smo was found in 12 (33.3%), 5 (13.9%), 5 (13.9%), and 6 (16.7%), respectively. We found that high expression of Shh was associated with worse progression free survival (6.3 vs. 7.6 months, p < 0.01) and overall survival (9.2 vs. 12.0 months), whereas other markers were not related to the prognosis of patients.

Conclusions

To our knowledge, this is the first report of the relationship between components of the Shh signaling pathway and prognosis in SCLC. We found that a high proportion of tumors expressed proteins related to this pathway, and over-expression of Shh was correlated with worse survival in this analysis. Shh signaling in SCLC requires further investigation using a larger sample size.

Clinical trial identification

Legal entity responsible for the study

IRB.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.